Since PPARα is abundantly expressed in the liver, known as a key regulator of lipid metabolism, and downregulated in MASLD patients correlating with the disease stage, several agonists have been therapeutically evaluated over the years (Francque et al., 2015; Kersten and Stienstra, 2017). Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.